Literature DB >> 29130787

miR-19a and miR-424 target TGFBR3 to promote epithelial-to-mesenchymal transition and migration of tongue squamous cell carcinoma cells.

Duo Li1, Ke Liu1, Zhiyong Li1, Jian Wang2, Xiaofeng Wang1.   

Abstract

Previous studies indicate that TGFBR3 (transforming growth factor type III receptor, also known as betaglycan), a novel suppressor of progression in certain cancers, is down-regulated in tongue squamous cell carcinoma (TSCC). However, the role of this factor as an upstream regulator in TSCC cells remains to be elucidated. The present study was designed to elucidate whether TGFBR3 gene expression is regulated by two microRNA molecules, miR-19a and miR-424. The study also aimed to determine if these microRNAs promote migration of CAL-27 human oral squamous cells. Immunohistochemistry (IHC) and western blot analyses demonstrated that TGFBR3 protein levels were dramatically down-regulated in clinical TSCC specimens. Conversely, bioinformatics analyses and qRT-PCR results confirmed that both miR-19a and miR-424 were markedly up-regulated in clinical TSCC specimens. In this study, we observed that transfection of a TGFBR3-containing plasmid dramatically inhibited epithelial-to-mesenchymal transition (EMT) and migration in CAL-27 cells. Co-immunoprecipitation analyses also revealed that TGFBR3 forms a complex with the β-arrestin 2 scaffolding protein and IκBα. Furthermore, overexpression of TGFBR3 decreased p-p65 expression and increased IκBα expression; these effects were subsequently abolished following knockdown of β-arrestin 2. Moreover, over-expression of miR-19a and miR-424 promoted migration and EMT in CAL-27 cells. We also observed that the promotion of EMT by miR-19a and miR-424 was mediated by the inhibition of TGFBR3. Our study provides evidence that miR-19a and miR-424 play important roles in the development of TSCC. These results expand our understanding of TGFBR3 gene expression and regulatory mechanisms pertaining to miRNAs.

Entities:  

Keywords:  EMT; TGFBR3; miR-19a; miR-424; migration; tongue squamous cell carcinoma

Mesh:

Substances:

Year:  2017        PMID: 29130787      PMCID: PMC6149514          DOI: 10.1080/19336918.2017.1365992

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


  36 in total

1.  beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha.

Authors:  D Scott Witherow; Tiffany Runyan Garrison; William E Miller; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-01       Impact factor: 11.205

2.  Type III Transforming Growth Factor-β Receptor Drives Cardiac Hypertrophy Through β-Arrestin2-Dependent Activation of Calmodulin-Dependent Protein Kinase II.

Authors:  Jie Lou; Dan Zhao; Ling-Ling Zhang; Shu-Ying Song; Yan-Chao Li; Fei Sun; Xiao-Qing Ding; Chang-Jiang Yu; Yuan-Yuan Li; Mei-Tong Liu; Chang-Jiang Dong; Yong Ji; Hongliang Li; Wenfeng Chu; Zhi-Ren Zhang
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

3.  Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway.

Authors:  Wei Li; Jiguang Ma; Qingyong Ma; Bin Li; Liang Han; Jiangbo Liu; Qinhong Xu; Wanxing Duan; Shuo Yu; Fengfei Wang; Erxi Wu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

4.  MicroRNA-328, a Potential Anti-Fibrotic Target in Cardiac Interstitial Fibrosis.

Authors:  Weijie Du; Haihai Liang; Xu Gao; Xiaoxue Li; Yue Zhang; Zhenwei Pan; Cui Li; Yuying Wang; Yanxin Liu; Wei Yuan; Ning Ma; Wenfeng Chu; Hongli Shan; Yanjie Lu
Journal:  Cell Physiol Biochem       Date:  2016-08-09

5.  MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer.

Authors:  Weidong Lu; Zhen Xu; Min Zhang; Yun Zuo
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 6.  Roles for the type III TGF-beta receptor in human cancer.

Authors:  Catherine E Gatza; Sun Young Oh; Gerard C Blobe
Journal:  Cell Signal       Date:  2010-02-12       Impact factor: 4.315

7.  The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.

Authors:  Jason D Lee; Nadine Hempel; Nam Y Lee; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2009-12-02       Impact factor: 4.944

8.  The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors.

Authors:  Nam Y Lee; Kellye C Kirkbride; Richard D Sheu; Gerard C Blobe
Journal:  Mol Biol Cell       Date:  2009-09-02       Impact factor: 4.138

9.  Downregulation of TGF-beta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated fibroblasts.

Authors:  Wenxia Meng; Qingjie Xia; Lanyan Wu; Sixiu Chen; Xin He; Lin Zhang; Qinghong Gao; Hongmei Zhou
Journal:  BMC Cancer       Date:  2011-02-28       Impact factor: 4.430

10.  Hsa-miR-19a is associated with lymph metastasis and mediates the TNF-α induced epithelial-to-mesenchymal transition in colorectal cancer.

Authors:  Lanlan Huang; Xiaoyan Wang; Chuangyu Wen; Xiangling Yang; Minmin Song; Junxiong Chen; Chenliang Wang; Bo Zhang; Lei Wang; Aikichi Iwamoto; Jianping Wang; Huanliang Liu
Journal:  Sci Rep       Date:  2015-08-25       Impact factor: 4.379

View more
  14 in total

1.  TRG-AS1 is a potent driver of oncogenicity of tongue squamous cell carcinoma through microRNA-543/Yes-associated protein 1 axis regulation.

Authors:  Shuwei He; Xu Wang; Jingjing Zhang; Fan Zhou; Lei Li; Xingmin Han
Journal:  Cell Cycle       Date:  2020-07-02       Impact factor: 4.534

Review 2.  Role of miRNA-19a in Cancer Diagnosis and Poor Prognosis.

Authors:  Alessio Ardizzone; Giovanna Calabrese; Michela Campolo; Alessia Filippone; Dario Giuffrida; Francesca Esposito; Cristina Colarossi; Salvatore Cuzzocrea; Emanuela Esposito; Irene Paterniti
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

3.  The STAT3-miR-223-TGFBR3/HMGCS1 axis modulates the progression of cervical carcinoma.

Authors:  Ju Zhang; Ming Jiang; Lili Qian; Xiao Lin; Weiguo Song; Yunfeng Gao; Ying Zhou
Journal:  Mol Oncol       Date:  2020-07-01       Impact factor: 6.603

4.  Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma.

Authors:  Yuhang Hu; Jiaao Gu; Hongtao Shen; Tuo Shao; Song Li; Wei Wang; Zhange Yu
Journal:  J Clin Lab Anal       Date:  2019-10-22       Impact factor: 2.352

5.  Exosomal CircGDI2 Suppresses Oral Squamous Cell Carcinoma Progression Through the Regulation of MiR-424-5p/SCAI Axis.

Authors:  Yu Zhang; Kaiqi Tang; Lizhu Chen; Meng Du; Zhi Qu
Journal:  Cancer Manag Res       Date:  2020-08-20       Impact factor: 3.989

6.  Circulating microRNA Panel as a Potential Novel Biomarker for Oral Squamous Cell Carcinoma Diagnosis.

Authors:  Kodai Nakamura; Naomi Hiyake; Tomofumi Hamada; Seiya Yokoyama; Kazuki Mori; Kouta Yamashiro; Mahiro Beppu; Yasuaki Sagara; Yoshiaki Sagara; Tsuyoshi Sugiura
Journal:  Cancers (Basel)       Date:  2021-01-25       Impact factor: 6.639

Review 7.  TGF-β superfamily co-receptors in cancer.

Authors:  John B Pawlak; Gerard C Blobe
Journal:  Dev Dyn       Date:  2021-04-09       Impact factor: 3.780

8.  lncRNA CCAT2 Enhanced Resistance of Glioma Cells Against Chemodrugs by Disturbing the Normal Function of miR-424.

Authors:  Jun Ding; Lin Zhang; Shiwen Chen; Heli Cao; Chen Xu; Xuyang Wang
Journal:  Onco Targets Ther       Date:  2020-02-17       Impact factor: 4.147

9.  MiR-26a/miR-26b represses tongue squamous cell carcinoma progression by targeting PAK1.

Authors:  Zhenxing Wei; Kunpeng Chang; Chongsheng Fan; Yang Zhang
Journal:  Cancer Cell Int       Date:  2020-03-14       Impact factor: 5.722

Review 10.  MicroRNAs and their role in the malignant transformation of oral leukoplakia: a scoping review.

Authors:  S Niklander; D Guerra; F Contreras; W González-Arriagada; C Marín
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2022-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.